Accelerate Diagnostics (NASDAQ:AXDX) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Accelerate Diagnostics (NASDAQ:AXDX) announced its earnings results on Thursday. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.13, Zacks reports. The company had revenue of $2.82 million for the quarter, compared to the consensus estimate of $3.00 million.

Accelerate Diagnostics Trading Down 6.2 %

NASDAQ AXDX traded down $0.07 on Friday, hitting $1.06. 156,774 shares of the company were exchanged, compared to its average volume of 59,715. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $2.09. The company has a market cap of $26.55 million, a P/E ratio of -0.37 and a beta of 0.55. The firm has a 50 day moving average of $1.16 and a two-hundred day moving average of $1.45.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on AXDX shares. BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a research report on Wednesday, December 11th. StockNews.com started coverage on shares of Accelerate Diagnostics in a report on Monday, March 17th. They issued a “hold” rating on the stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.